Akira Iyobe
Kyoto Pharmaceutical University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Akira Iyobe.
Ophthalmic Research | 1998
Yasunori Segawa; Yutaka Shirao; Sho-ichi Yamagishi; Tomomi Higashide; Miho Kobayashi; Kenji Katsuno; Akira Iyobe; Hiromu Harada; Fumiyasu Sato; Hiroshi Miyata; Hiroshi Asai; Akira Nishimura; Masayuki Takahira; Tsutomu Souno; Youji Segawa; Kazuhiko Maeda; Kenji Shima; Akira Mizuno; Hiroshi Yamamoto; Kazuo Kawasaki
Vascular endothelial growth factor (VEGF) has recently been shown to be involved in the pathogenesis of proliferative diabetic retinopathy. However, its involvement in the development of the early phase of diabetic retinopathy is not fully understood. In this study we investigated the retinal VEGF mRNA level in spontaneously diabetic Otsuka Long-Evans Tokushima fatty (OLETF) rats, a model of non-insulin-dependent diabetes, without overt retinopathy, using quantitative reverse-transcription polymerase chain reaction. The retinal VEGF mRNA level was 2.2 times higher (p < 0.0005) in OLETF rats than in control rats at the age of 60 weeks. Moreover, their retinal mRNA level was positively correlated with serum concentration of advanced glycation end products (AGEs) but not to serum glucose concentration. Furthermore, the peak latency of the oscillatory potentials in the electroretinogram, one of the most sensitive markers for the early phase of diabetic retinopathy, was significantly prolonged in OLETF rats (p < 0.05), being also correlated with the serum AGE concentration. The results thus suggest that AGEs, which are formed acceleratedly in diabetic conditions, are involved in the development of the early phase of diabetic retinopathy probably through the induction of retinal VEGF mRNAs.
Journal of The Chemical Society-perkin Transactions 1 | 1990
Hiromu Harada; Akira Iyobe; Atsushi Tsubaki; Toshiaki Yamaguchi; Kazuma Hirata; Tetsuhide Kamijo; Kinji Iizuka; Yoshiaki Kiso
The practical synthesis of an orally potent human renin inhibitor, isopropyl (2R,3S)-4-cyclohexyl-2-hydroxy-3-{N-[(2R)-2-morpholinocarbonylmethyl-3-(1-naphthyl)propionyl]-L-histidyl}-aminobutyrate, is presented. Optically pure cyclohexylnorstatine isopropyl ester (P1–P1′ moiety) was diastereoselectively and simply prepared from L-phenylalanine methyl ester. In a one-pot reaction, N-[(2R)-2-morpholinocarbonylmethyl-3-(1-naphthyl)propionyl]-L-histidine methyl ester (P4–P2moiety) was conveniently hydrolysed, protected with a Boc group attached to the side-chain imidazole function, and coupled with the cyclohexylnorstatine ester to give the optically pure target renin inhibitor.
Archive | 2000
Hideki Fujikura; Toshihiro Nishimura; Kenji Katsuno; Masahiro Hiratochi; Akira Iyobe; Minoru Fujioka; Masayuki Isaji
Chemical & Pharmaceutical Bulletin | 2001
Akira Iyobe; Masahiko Uchida; Kouji Kamata; Yukihiko Hotei; Hiroshi Kusama; Hiromu Harada
Chemical & Pharmaceutical Bulletin | 1987
Hiromitsu Takayama; Akira Iyobe; Toru Koizumi
Archive | 2003
Akira Iyobe; Hirotaka Teranishi; Kazuya Tatani; Shigeru Yonekubo; Masayuki Isaji
Archive | 1996
Hidenori Fujikura; Kazumitsu Hirata; Akira Iyobe; Kiyoshi Kasai; Fumiyasu Sato; Toshikazu Yazaki; 亮 伊與部; 文康 佐藤; 一満 平田; 潔 河西; 敏和 矢崎; 秀紀 藤倉
Journal of Organic Chemistry | 1990
Hiromu Harada; Toshiaki Yamaguchi; Akira Iyobe; Atsushi Tsubaki; Tetsuhide Kamijo; Kinji Iizuka; Katsuyuki Ogura; Yoshiaki Kiso
Archive | 1996
Hidenori Fujikura; Kazumitsu Hirata; Akira Iyobe; Koji Kamata; Kiyoshi Kasai; Fumiyasu Sato; Toshikazu Yazaki; 亮 伊與部; 文康 佐藤; 一満 平田; 潔 河西; 敏和 矢崎; 秀紀 藤倉; 晃爾 鎌田
Archive | 1996
Hidenori Fujikura; Hiroshi Harada; Akira Iyobe; Koji Kamata; Kiyoshi Kasai; Fumiyasu Sato; Toshikazu Yazaki; 亮 伊與部; 文康 佐藤; 弘 原田; 潔 河西; 敏和 矢崎; 秀紀 藤倉; 晃爾 鎌田